Endometrial Carcinoma Gene-Edited Cell Lines for Drug Discovery

Endometrial carcinoma is the most common gynecologic malignancy in developed countries. According to the World Health Organization (WHO), there were approximately 417,000 new cases and 97,000 deaths globally in 2020. The National Cancer Institute (NCI) reports a 5-year survival rate of 95% for localized disease, which drops to 18% for distant-stage disease. Key risk factors include obesity, unopposed estrogen exposure, and Lynch syndrome. Rising incidence, especially in younger women, underscores the need for better therapeutic strategies and preclinical models.

Endometrial carcinoma is ideal for mechanistic studies due to its well-defined molecular subtypes (POLE ultramutated, microsatellite instability hypermutated, copy-number low, copy-number high) as defined by The Cancer Genome Atlas (TCGA). Public datasets from TCGA, cBioPortal, and DepMap provide rich genomic and functional data. Open questions include mechanisms of hormone-independent growth, immune evasion, and resistance to targeted therapies such as PI3K/AKT/mTOR inhibitors.

Endometrial carcinoma arises from the interplay of several pathways:

1. PI3K/AKT/mTOR pathway: Activating mutations in PIK3CA (52%) and loss of PTEN (77%) lead to uncontrolled cell growth and survival.

2. Wnt/β-catenin pathway: CTNNB1 exon 3 mutations (25%) cause nuclear accumulation of β-catenin, driving proliferation.

3. RAS/MAPK pathway: KRAS mutations (10-20%) activate downstream signaling, promoting cell cycle progression.

4. DNA mismatch repair (MMR) deficiency: MLH1 promoter hypermethylation or MSH2/MSH6 mutations (30%) result in microsatellite instability and hypermutation.

Data from TCGA and COSMIC (Catalogue of Somatic Mutations in Cancer).

Key signaling networks include:

• • PI3K/AKT/mTOR: PTEN loss, PIK3CA mutation, AKT phosphorylation, mTORC1/2 activation.
• • Wnt/β-catenin: CTNNB1 mutation, APC loss, TCF/LEF transcription.
• • MAPK/ERK: KRAS mutation, BRAF mutation (rare), MEK/ERK phosphorylation.
• • Chromatin remodeling: ARID1A loss, SWI/SNF complex dysfunction.
• • DNA damage repair: TP53 mutation, MMR deficiency, POLE exonuclease domain mutations.

Common endometrial carcinoma cell lines and their key mutations:

Organoids derived from patient tumors retain histological and genetic features, enabling drug testing and personalized medicine studies.

Animal models for endometrial carcinoma include:

• • Patient-derived xenografts (PDX): Engraftment of human tumors in immunodeficient mice, preserving tumor heterogeneity.
• • Genetically engineered mouse models (GEMM): Conditional knockout of Pten and/or activation of Kras in the uterine epithelium (e.g., Ptenfl/fl;KrasLSL-G12D).
• • Induced models: Administration of estrogen and carcinogens (e.g., N-methyl-N-nitrosourea) to induce tumors.

CRISPR/Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications. Examples include:

• • TP53 knockout: Loss of p53 function in wild-type TP53 cell lines (e.g., Ishikawa) to model copy-number high subtype.
• • KRAS G12D knock-in: Introduction of activating KRAS mutation in wild-type lines to study MAPK pathway dependence.
• • PTEN knockout: Complete loss of PTEN to model PI3K pathway addiction.
• • ARID1A knockout: Disruption of chromatin remodeling to study synthetic lethality.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible, isogenic controls for functional studies and drug screening.

Gene-edited cell lines enable direct functional validation of candidate oncogenes and tumor suppressors. For example:

• • PTEN knockout in Ishikawa cells confirms its role in AKT activation and cell proliferation.
• • ARID1A knockout in HEC-1A cells demonstrates its impact on chromatin accessibility and gene expression.
• • KRAS G12D knock-in in KLE cells allows study of MAPK signaling and drug sensitivity.

Isogenic pairs (e.g., wild-type vs. PTEN knockout) are used in high-throughput screens to identify compounds that selectively target mutant cells. Resistance mechanisms can be modeled by chronic drug exposure in gene-edited lines, revealing secondary mutations or pathway rewiring.

CRISPR-based synthetic lethality screens identify genes essential only in specific genetic backgrounds. For example, ARID1A-mutant cells are vulnerable to EZH2 inhibitors, a finding validated using ARID1A knockout lines. Such screens guide biomarker development for patient stratification.